Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial

Kuan Pin Su, Shih Yi Huang, Tsan Hung Chiu, Kuo Cherh Huang, Chieh Liang Huang, Hui Chih Chang, Carmine M. Pariante

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Background: Perinatal depression is common, and treatment remains challenging. Depression has been reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease of omega-3 PUFAs in the mother during pregnancy is associated with the higher demand of fetal development and might precipitate the occurrence of depression. In this study, we examined the efficacy of omega-3 PUFA monotherapy for the treatment of depression during pregnancy. Method: From June 2004 to June 2006, we conducted an 8-week, double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with placebo in pregnant women with major depressive disorder (DSMIV criteria). No psychotropic agent was given 1 month prior to or during the study period. The Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI) were secondary measures. Results: Thirty-six subjects were randomly assigned to either omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2 visits. A total of 24 subjects completed the study. As compared to the placebo group, subjects in the omega-3 group had significantly lower HAM-D scores at weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62% vs. 27%, p = .03), and a higher remission rate, although the latter did not reach statistical significance (38% vs. 18%, p = .28). At the study end point, subjects in the omega-3 group also had significantly lower depressive symptom ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there were no adverse effects on the subjects and newborns. Conclusions: Omega-3 PUFAs may have therapeutic benefits in depression during pregnancy. In regard to the safety issue and psychotherapeutic effect, as well as health promotion to mothers and their newborns, it is worthy to conduct replication studies in a larger sample with a broad regimen of omega-3 PUFAs in pregnant women with depression. Trial Registration: clinicaltrials.gov Identifier: NCT00618865.

Original languageEnglish
Pages (from-to)644-651
Number of pages8
JournalJournal of Clinical Psychiatry
Volume69
Issue number4
Publication statusPublished - Apr 2008

Fingerprint

Major Depressive Disorder
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Placebos
Depression
Pregnancy
Postpartum Depression
Pregnant Women
Mothers
Newborn Infant
Equipment and Supplies
Fetal Development
Health Promotion
Therapeutics
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Omega-3 fatty acids for major depressive disorder during pregnancy : Results from a randomized, double-blind, placebo-controlled trial. / Su, Kuan Pin; Huang, Shih Yi; Chiu, Tsan Hung; Huang, Kuo Cherh; Huang, Chieh Liang; Chang, Hui Chih; Pariante, Carmine M.

In: Journal of Clinical Psychiatry, Vol. 69, No. 4, 04.2008, p. 644-651.

Research output: Contribution to journalArticle

Su, Kuan Pin ; Huang, Shih Yi ; Chiu, Tsan Hung ; Huang, Kuo Cherh ; Huang, Chieh Liang ; Chang, Hui Chih ; Pariante, Carmine M. / Omega-3 fatty acids for major depressive disorder during pregnancy : Results from a randomized, double-blind, placebo-controlled trial. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. 4. pp. 644-651.
@article{285801305ff840f1b2e9bc9782f351fc,
title = "Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial",
abstract = "Background: Perinatal depression is common, and treatment remains challenging. Depression has been reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease of omega-3 PUFAs in the mother during pregnancy is associated with the higher demand of fetal development and might precipitate the occurrence of depression. In this study, we examined the efficacy of omega-3 PUFA monotherapy for the treatment of depression during pregnancy. Method: From June 2004 to June 2006, we conducted an 8-week, double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with placebo in pregnant women with major depressive disorder (DSMIV criteria). No psychotropic agent was given 1 month prior to or during the study period. The Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI) were secondary measures. Results: Thirty-six subjects were randomly assigned to either omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2 visits. A total of 24 subjects completed the study. As compared to the placebo group, subjects in the omega-3 group had significantly lower HAM-D scores at weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62{\%} vs. 27{\%}, p = .03), and a higher remission rate, although the latter did not reach statistical significance (38{\%} vs. 18{\%}, p = .28). At the study end point, subjects in the omega-3 group also had significantly lower depressive symptom ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there were no adverse effects on the subjects and newborns. Conclusions: Omega-3 PUFAs may have therapeutic benefits in depression during pregnancy. In regard to the safety issue and psychotherapeutic effect, as well as health promotion to mothers and their newborns, it is worthy to conduct replication studies in a larger sample with a broad regimen of omega-3 PUFAs in pregnant women with depression. Trial Registration: clinicaltrials.gov Identifier: NCT00618865.",
author = "Su, {Kuan Pin} and Huang, {Shih Yi} and Chiu, {Tsan Hung} and Huang, {Kuo Cherh} and Huang, {Chieh Liang} and Chang, {Hui Chih} and Pariante, {Carmine M.}",
year = "2008",
month = "4",
language = "English",
volume = "69",
pages = "644--651",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Omega-3 fatty acids for major depressive disorder during pregnancy

T2 - Results from a randomized, double-blind, placebo-controlled trial

AU - Su, Kuan Pin

AU - Huang, Shih Yi

AU - Chiu, Tsan Hung

AU - Huang, Kuo Cherh

AU - Huang, Chieh Liang

AU - Chang, Hui Chih

AU - Pariante, Carmine M.

PY - 2008/4

Y1 - 2008/4

N2 - Background: Perinatal depression is common, and treatment remains challenging. Depression has been reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease of omega-3 PUFAs in the mother during pregnancy is associated with the higher demand of fetal development and might precipitate the occurrence of depression. In this study, we examined the efficacy of omega-3 PUFA monotherapy for the treatment of depression during pregnancy. Method: From June 2004 to June 2006, we conducted an 8-week, double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with placebo in pregnant women with major depressive disorder (DSMIV criteria). No psychotropic agent was given 1 month prior to or during the study period. The Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI) were secondary measures. Results: Thirty-six subjects were randomly assigned to either omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2 visits. A total of 24 subjects completed the study. As compared to the placebo group, subjects in the omega-3 group had significantly lower HAM-D scores at weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62% vs. 27%, p = .03), and a higher remission rate, although the latter did not reach statistical significance (38% vs. 18%, p = .28). At the study end point, subjects in the omega-3 group also had significantly lower depressive symptom ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there were no adverse effects on the subjects and newborns. Conclusions: Omega-3 PUFAs may have therapeutic benefits in depression during pregnancy. In regard to the safety issue and psychotherapeutic effect, as well as health promotion to mothers and their newborns, it is worthy to conduct replication studies in a larger sample with a broad regimen of omega-3 PUFAs in pregnant women with depression. Trial Registration: clinicaltrials.gov Identifier: NCT00618865.

AB - Background: Perinatal depression is common, and treatment remains challenging. Depression has been reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease of omega-3 PUFAs in the mother during pregnancy is associated with the higher demand of fetal development and might precipitate the occurrence of depression. In this study, we examined the efficacy of omega-3 PUFA monotherapy for the treatment of depression during pregnancy. Method: From June 2004 to June 2006, we conducted an 8-week, double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with placebo in pregnant women with major depressive disorder (DSMIV criteria). No psychotropic agent was given 1 month prior to or during the study period. The Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale (EPDS) and Beck Depression Inventory (BDI) were secondary measures. Results: Thirty-six subjects were randomly assigned to either omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2 visits. A total of 24 subjects completed the study. As compared to the placebo group, subjects in the omega-3 group had significantly lower HAM-D scores at weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62% vs. 27%, p = .03), and a higher remission rate, although the latter did not reach statistical significance (38% vs. 18%, p = .28). At the study end point, subjects in the omega-3 group also had significantly lower depressive symptom ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there were no adverse effects on the subjects and newborns. Conclusions: Omega-3 PUFAs may have therapeutic benefits in depression during pregnancy. In regard to the safety issue and psychotherapeutic effect, as well as health promotion to mothers and their newborns, it is worthy to conduct replication studies in a larger sample with a broad regimen of omega-3 PUFAs in pregnant women with depression. Trial Registration: clinicaltrials.gov Identifier: NCT00618865.

UR - http://www.scopus.com/inward/record.url?scp=44849092681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849092681&partnerID=8YFLogxK

M3 - Article

C2 - 18370571

AN - SCOPUS:44849092681

VL - 69

SP - 644

EP - 651

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -